Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record.

Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone

Hou, Z.-Y., CHANG, M.-S., CHEN, C.-Y., TU, M.-S., LIN, S.-L., CHIANG, H.-T., WOOSLEY, R. L. · 1995 · European Heart Journal

Abstract

A 24 h intravenous dosing regimen of amiodarone was designed to reach a peak plasma concentration at 1 h and to maintain the concentration above a certain level during the infusion period A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats. min−1. Fifty patients with a mean age of 70 ± 7 (SD) years were enrolled and randomly assigned to receive either amiodarone intravenously (n=26) or digoxin (n=24). Amiodarone HCl was infused over 24 h according to the following regimen: 5 mg. min−1, 3 mg. min−1, 1 mg. min−1 and 0.5 mg. min−1 for 1, 3, 6 and 14 h, respectively, for a 70-kg subject. Digoxin (0.013 mg. kg−1) was infused in three divided doses, each dose 2 h apart and infused over 30 min. The mean heart rates in the amiodarone group decreased significantly from 157 ± 20 beats. min−1 to 122 ± 25 beats. min−1 after 1 h (P<005 vs baseline), and then decreased further to stabilize at 96 ± 25 beats. min−1 after 6 h (P<0.05). The digoxin group had fewer dramatic alterations in heart rates, compared to the amiodarone group, in the first 8h (P<0.05, respectively). Maximum reduction was reached only after 8 h. The amiodarone infusion was prematurely aborted in two patients due to severe bradycardia and death after conversion in one patient and aggravation of heart failure in the other. Overall, 24 of 26 patients (92%) in the amiodarone group and 17 of 24 (71%) in the digoxin group were restored to sinus rhythm within 24 h. The accumulated rates of conversion over 24 h were significantly different between the two groups (P=0.0048). Digoxin, while not as effective as amiodarone in the treatment of recent-onset atrial fibrillation and flutter, appears to be safer. Therefore, we suggest the use of digoxin as the first line drug for the type of patients that formed the basis of the current study and reserve amiodarone for refractory cases or those in whom digoxin is not suitable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/oxfordjournals.eurheartj.a060945

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Hou, Z.-Y., CHANG, M.-S., CHEN, C.-Y., TU, M.-S., LIN, S.-L., CHIANG, H.-T., & WOOSLEY, R. L.
Venue
European Heart Journal
Published
1995-04
Volume
16
Issue
4
Pages
521-528
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2227504580
Cited by
178
References
0
FWCI
4.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. https://app.cochat.ai/papers/10.1093/oxfordjournals.eurheartj.a060945
The paper
Hou, Z.-Y., CHANG, M.-S., CHEN, C.-Y., TU, M.-S., LIN, S.-L., CHIANG, H.-T., & WOOSLEY, R. L. (1995). Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. European Heart Journal. https://doi.org/10.1093/oxfordjournals.eurheartj.a060945

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.